Levels of p-EGFR (Y1068), p-AKT (T308) and VEGFR2 in prostate cancer cells were reduced after Enzalumide combined with CCX771 (a CXCR7 inhibitor) compared with single drug therapy (Luo et al., 2018). Here, ACKR3 is linked to prostate cancer.